Together, the present study demonstrates that directly tethering cytokines to the T cell surface by fusing to an antibody targeting highly expressed cell surface receptors safely harnesses the cytokine activity to improve the efficacy of ACT in both immune-suppressed (B16-F10 melanoma) and inflamed (CT26 colon carcinoma) tumor models. This evidence concerns the gene CD177 and melanoma.